Embed Size (px)
Citation preview
Translational Product development Access
SJ733St Jude/Eisai
MMV048UCT/TIA
Rectal Artesunate *Cipla/Strides/WHO-TDR
PreclinicalPatient
confirmatoryPost approval Human
volunteersPatient
exploratoryRegulatory
review 1 projectNovartis
P218(Biotec)
DSM265UTSW/UW/Monash
TafenoquineGSK
2 projectsGSK
Orthologue LeadsSanofi
TetraoxanesLSTM/Liverpool
DHODHUTSW/UW/Monash
Open Source Drug DiscoveryUniv. Sydney
Pf NMTImperial CollegeLondon
PA92 (Drexel/UW/GNF)
MMV253(AstraZeneca)
OZ439/FQSanofi
KAE609Novartis
KAF156Novartis
Artesunate for injection Guilin
Dihydroartemisinin-piperaquine Sigma-Tau
Pyronaridine-artesunateShin Poong
Artesunate-amodiaquine *
Sanofi/ DNDi
Artesunate-mefloquine *
Cipla/DNDi
Global Portfolio of Antimalarial Medicines2016
GSK030GSK
DSM421(UTSW/UW/Monash)
Pyronaridine-artesunate PaediatricShin Poong
SPAQGuilin
Dihydroartemisinin -piperaquinePaediatricSigma-Tau
ResearchLead
optimization
3
1
2
4
5
6
DDD498Merck Serono(Dundee)
NPC1161BMississippi
JPC2997Jacobus
MK4815Merck
ACT-451840Actelion
UCT
dUTPaseInhibitorsMedivir
HeterocyclesCelgene
Whole cellSt Jude/Rutgers/USF
Diversity OrientedSynthesisBroad/Eisai
ImidazolidinedionesWRAIR
Pf NDH2Imperial CollegeLondon
PantothenamidesTropIQ/RUMC/Pansynt
CDRI 9778Ipca
N-tert butyl Isoquine
LSTM/Liverpool/GSK
FosmidomycinPiperaquineJomaa Pharma/GmbH
MethyleneBlue/AQHeidelberg
SAR97276Sanofi
ArtemisoneUHKST
AQ13Immtech
SevuparinDilaforette
Co-trimoxazoleITM Antwerp
Artemisinin Naphthoquine * *
KPC
Artemether sub-lingual spray Photo Pharma Ltd
Arterolane/PiperaquineSun Pharmac* *
AN762Anacor
www.mmv.org
Artemether-lumefantrineDispersibleNovartis
Asexual blood stage activity
Relapse prevention
Transmission reduction (gametocytocidal or sporontocidal)
Chemoprevention
Brought into portfolio after approval. Collaboration with DNDi
No progress report in the last two years
December 2016
Global Portfolio of Antimalarial Medicines 2017
Translational Product development AccessPreclinical
Patient confirmatory
Assessed/Approved
Human volunteers
Patient exploratory
Regulatory review
GSK030GlaxoSmithKline
DSM421Takeda(UTSW/UW/Monash)
AN13762(Anacor)
UCT943UCT
NPC1161BMississippi
MK4815Merck
P218(Biotec Thailand)
SJ733St Jude/Eisai
DSM265Takeda(UTSW/UW/Monash)
Artefenomel/FerroquineSanofi
Cipargamin
Novartis
KAF156/Lumefantrine Novartis
Dihydroartemisinin piperaquinePaediatricSigma-Tau/Pierre Fabre
Artesunate for Injection Guilin
Dihydroartemisinin-piperaquine Sigma-Tau /Pierre Fabre
Pyronaridine-ArtesunatetabletsShin Poong
3
2
4
Artemether-lumefantrineVarious Manufactures
6
Artesunate-mefloquineCipla/DNDi/Farmanguinhos
5
1
5
ACT-451840Actelion
CDRI 9778Ipca
N-tert butyl IsoquineLSTM/Liverpool/GSK
MethyleneBlue/AQHeidelberg
SAR97276Sanofi
ArtemisoneUHKST
AQ13Immtech
SevuparinDilaforette
FosmidomycinPiperaquineJomaa Pharma/GmbH
7
Co-trimoxazoleITM Antwerp
Artemether sub-lingual spray MRC/Suda
Artemisinin naphthoquineKunming Pharma Co
†
Tafenoquine GSK/MMVGSK/US Army
Arterolane/piperaquineSun Pharma
†
3
Artemether-lumefantrineDispersibleVarious Manufacturers
Pyronaridine-artesunate granulesShin Poong
Artesunate-amodiaquineVariousManufacturers
Sulfadoxinepyrimethamine+amodiaquine *Guilin
PA92 (Drexel/UW/GNF)
MMV253Zydus Cadila(AstraZeneca)
JPC3210Jacobus
GSK607GlaxoSmithKline
DDD498Merck KGaA(Dundee)
MMV048(UCT)
Rectal artesunateCipla/Strides/WHO-TDR
7
Sulfadoxinepyrimethamine+amodiaquine ** Guilin
Asexual blood stage activity
Relapse prevention
Transmission reduction (gametocytocidal or sporontocidal)
Chemoprevention
Brought into portfolio after approval. Collaboration with DNDi
No progress report in the last two years
Patient confirmatory Regulatory review
DSM265Takeda(UTSW/UW/Monash)
Artefenomel/FerroquineSanofi
Cipargamin
Novartis
KAF156/Lumefantrine Novartis
Dihydroartemisinin piperaquinePaediatricSigma-Tau/Pierre Fabre
Methylene Blue/AQHeidelberg
SAR97276Sanofi
ArtemisoneUHKST
AQ13Immtech
SevuparinDilaforette
Fosmidomycin PiperaquineJomaa Pharma/GmbH
Co-trimoxazoleITM Antwerp
Artemether sub-lingual spray MRC/Suda
Artemisinin naphthoquineKunming Pharma Co
†
Tafenoquine GSK/MMVGSK/US Army
Arterolane/piperaquineSun Pharma
†
3
Asexual blood stage activity
Relapse prevention
Transmission reduction (gametocytocidal or sporontocidal)
Chemoprevention
Brought into portfolio after approval. Collaboration with DNDi
No progress report in the last two years
Approved in several countries but not approved by WHO pre-
qualification nor regulatory bodies who are ICH members or
observers
MMV048(UCT)
SERCaP - Single Exposure Radical Cure and Prophylaxis
SEC - Single Exposure Chemoprotection
†
Cochrane Database Syst Rev.
Antimicrob Agents Chemother.
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
